Capital Fund Management (CFM)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capital Fund Management (CFM)’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,600	Closed	-$437K	–	2039
2018 Q3	$437K	Sell	2,600 -200	-7%	-$34.4K	﹤0.01%	1646
2018 Q2	$482K	Buy	+2,800	New	+$458K	﹤0.01%	1608
2015 Q3	–	Sell	-2,000	Closed	-$352K	–	1530
2015 Q2	$352K	Hold	2,000	–	–	﹤0.01%	1201
2015 Q1	$346K	Sell	2,000 -3,000	-60%	-$515K	﹤0.01%	1173
2014 Q4	$819K	Sell	5,000 -2,600	-34%	-$432K	0.01%	954
2014 Q3	$1.22M	Sell	7,600 -5,900	-44%	-$907K	0.01%	855
2014 Q2	$1.99M	Buy	13,500 +3,000	+29%	+$416K	0.02%	722
2014 Q1	$1.46M	Buy	+10,500	New	+$1.58M	0.02%	803

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Capital Fund Management (CFM)'s JAZZ Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 40,275 shares — an estimated $4.27M sold.

Capital Fund Management (CFM) first reported a position in JAZZ in Q1 2014 and held it in 19 quarters. The position peaked at $10.4M in Q2 2016. 502 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

Capital Fund Management (CFM) reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 40,275 Jazz Pharmaceuticals shares in Q3 2025, an estimated $4.27M.
Capital Fund Management (CFM) first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 19 quarters.
Capital Fund Management (CFM)'s Jazz Pharmaceuticals position peaked at $10.4M in Q2 2016.
502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.